NCT04029649

Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

The Role of Beta-1,3/1,6-D-Glucan From Mycelium Extract of Indonesian Ganoderma Lucidum on Ulcerative Colitis: A Double-Blind Randomized Controlled Trial

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 204 (estimated)
• Sponsor: Fakultas Kedokteran Universitas Indonesia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	Beta-1,3/1,6-D-Glucan	Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
DRUG	Placebo	Placebo capsule three times daily for 90 days

Timeline

• Start date: 2019-08-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2019-07-23
• Last updated: 2019-08-02

Locations

1 site across 1 country: Indonesia